2025年中国药企对外授权活跃,截至10月创新药对外授权总金额达千亿美元,年末继续“多点开花、重点突破”。12月22日,荃信生物与先声药业同日宣布将核心创新药授权国际伙伴,交易总额达17.6亿美元。荃信生物与LE2025 Therapeutics AG签订协议,授权其全球(不含中国内地及港澳台)独家开发及商业化QX027N,将获7亿美元付款,QX027N拟用于治疗哮喘及特应性皮炎,12月已在中国...
Source Link2025年中国药企对外授权活跃,截至10月创新药对外授权总金额达千亿美元,年末继续“多点开花、重点突破”。12月22日,荃信生物与先声药业同日宣布将核心创新药授权国际伙伴,交易总额达17.6亿美元。荃信生物与LE2025 Therapeutics AG签订协议,授权其全球(不含中国内地及港澳台)独家开发及商业化QX027N,将获7亿美元付款,QX027N拟用于治疗哮喘及特应性皮炎,12月已在中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.